Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection
Sponsors
Shanghai Virogin Biotech Co., Ltd., Virogin Biotech Ltd.
Conditions
Advanced Malignant Solid Tumor
Phase 1
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors
RecruitingNCT05477849
Start: 2022-08-23End: 2025-12-31Target: 30Updated: 2025-04-01
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors
RecruitingNCT07262164
Start: 2026-03-18End: 2028-08-01Target: 30Updated: 2026-03-25
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of VG2025 Intravenous Injection in Subjects With Advanced Solid Tumors
Not yet recruitingNCT07682870
Start: 2026-09-04End: 2029-09-03Target: 42Updated: 2026-07-06